URGN logo

URGN UroGen Pharma Ltd.

NASDAQ · Biotechnology · Healthcare

$27.65
-4.08 (-12.86%)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder …

Market Cap: $1.36Bwww.urogen.com

Price

No data yet.

Social Signal Score

56
5d
50
1 mentions
—
30d
57
7 mentions
—
60d
58
9 mentions
—
90d
58
9 mentions
—
news: 9

Analyst Ratings

16 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 4Sell 0Strong Sell 0
Avg price target$58.6+111.9%
Low $44Median $58High $75
Current Consensus

Revenue

$89.00M+407.71%
$0.00$29.67M$59.33M$89.00M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-3.20
$-3.38–$-2.98
6 analysts
FY2026
$-0.37
$-0.79–$-0.11
6 analysts
FY2027
$2.50
$0.56–$4.40
6 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Elizabeth Barrett
Sector
Healthcare
Industry
Biotechnology
Employees
300
Beta
1.64
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-1.90
www.urogen.com